LYEL
Lyell Immunopharma Inc
8.70$
+0.0%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Lyell Immunopharma Inc (LYEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -34 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24 | -89 | -22 | -27 | -34 | -34 | -25 | -33 | -48 | -44 | -37 | -40 | -46 | -39 | -38 | -41 | -42 | -38 | -35 | -47 | -55 | -34 | -29 | -32 | -39 | -34 | -133 | |
| 0.8 | 1.0 | 1.1 | 1.5 | 3.0 | 3.0 | 4.1 | 4.0 | 4.0 | 3.7 | 4.2 | 4.6 | 5.0 | 4.5 | 5.1 | 5.1 | 5.0 | 4.9 | 4.7 | 5.0 | 3.4 | 3.1 | 2.6 | 2.4 | 2.3 | 2.2 | 9.5 | |
| 3.3 | 7.3 | 9.7 | 13 | 13 | 15 | 13 | 21 | 22 | 22 | 19 | 18 | 14 | 14 | 11 | 8.5 | 9.2 | 8.3 | 7.6 | 8.1 | 6.0 | 5.0 | 5.2 | 26 | 4.3 | 4.5 | 40 | |
| 5.4 | 13 | 13 | – | 24 | 26 | 14 | 42 | 22 | 22 | 25 | 6.5 | 14 | 15 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.5 | -2.3 | 0.4 | 2.1 | -4.8 | -0.6 | 5.7 | 3.6 | -2.4 | -38 | 1.7 | -43 | -4.3 | 3.6 | 2.4 | 1.7 | -3.2 | -1.0 | 1.0 | 0.0 | -9.6 | -0.9 | -0.1 | 0.7 | -1.1 | 7.9 | 7.3 | |
| 6.9 | 7.1 | 13 | 25 | 19 | 24 | 12 | 10 | 9.7 | 7.2 | 2.8 | 4.6 | 1.5 | 0.9 | 0.2 | 0.0 | 0.0 | 0.3 | 0.1 | 0.0 | 0.2 | 0.2 | 0.1 | 0.3 | 0.1 | 0.3 | 0.7 | |
| -116 | -100 | -90 | 32 | 137 | -39 | -145 | -74 | -26 | 25 | -57 | 47 | 32 | 153 | 100 | -101 | 22 | 45 | 1.9 | 54 | 69 | 13 | 3.3 | -31 | 17 | 16 | 5.0 | |
| -12 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.5 | 0.0 | 2.6 | 2.5 | -0.4 | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | -0.1 | 0.8 | -0.7 | 36 | – | – | – | – | – | – | – | |
| 476 | 0.0 | 0.0 | 0.3 | 0.9 | 393 | -0.5 | 7.4 | 2.6 | 2.5 | 4.8 | 0.9 | -0.1 | 1.2 | -0.1 | 0.8 | 0.0 | 0.9 | 0.0 | 0.4 | 0.0 | 0.2 | 50 | 0.2 | 52 | 0.5 | 102 | |
| 337 | -189 | -112 | 6.0 | 104 | 320 | -171 | -100 | -71 | -17 | -89 | 7.2 | -14 | 115 | 62 | -141 | -20 | 7.8 | -33 | 5.3 | 15 | -22 | 25 | -63 | 31 | -18 | -26 | |
| -30 | -96 | -34 | -52 | -53 | -58 | -37 | -43 | -58 | -52 | -40 | -45 | -48 | -40 | -38 | -41 | -42 | -38 | -35 | -47 | -55 | -35 | -29 | -33 | -39 | -34 | -134 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.